MGX Metagenomi Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1785279 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.7%
TTM net income YoY-10.2%
TTM EPS YoY-23.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-415.5%
Net margin-384.6%
FCF margin-392.0%
EBITDA margin-392.0%
Returns
ROE-49.0%
ROA-34.7%
ROIC (approx.)-49.5%
Asset turnover0.09x
Leverage & solvency
Liabilities / assets30.0%
Debt / equity0.00x
Current ratio6.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $25.21M | $52.30M |
| R&D expense | $94.43M | $109.18M |
| SG&A expense | $26.79M | $32.02M |
| Operating income | -$96.01M | -$88.90M |
| Pretax income | -$87.93M | -$83.57M |
| Income tax | -$58,000 | -$5.51M |
| Net income | -$87.87M | -$78.06M |
| EBITDA | -$90.70M | -$83.49M |
| EPS (basic) | -2.36 | -2.36 |
| EPS (diluted) | -2.36 | -2.36 |
| Weighted avg. shares (diluted) | 37.25M | 33.03M |
| Balance sheet | ||
| Cash & equivalents | $41.72M | $32.63M |
| Short-term investments | $119.08M | $220.92M |
| Receivables | $305,000 | $1.26M |
| Current assets | $165.54M | $257.96M |
| PP&E, net | $12.29M | $17.74M |
| Total assets | $221.10M | $324.60M |
| Current liabilities | $22.93M | $37.31M |
| Total liabilities | $62.51M | $89.74M |
| Shareholders' equity | $158.60M | $234.86M |
| Shares outstanding | 37.62M | 37.42M |
| Cash flow statement | ||
| Operating cash flow | -$88.89M | -$109.07M |
| Capital expenditure | $574,000 | $3.11M |
| Free cash flow | -$89.47M | -$112.19M |
| Investing cash flow | $103.53M | -$88.16M |
| Financing cash flow | -$356,000 | $84.01M |
| Depreciation & amortization | $5.32M | $5.41M |
| Stock-based compensation | $11.85M | $16.20M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.